Fairmount Funds Management is a registered investment adviser and healthcare-focused hedge fund based in West Conshohocken, Pennsylvania. The firm executes strategic equity investments across public and private biotechnology markets, targeting companies developing differentiated therapeutics.
86% of their portfolio is in Biotech & Life Sciences. Average disclosed round size is $222.7M (across 7 rounds with reported amounts).
Portfolio
7
Fund Size
—
Top Stage
Unknown
Last 12 Mo
0
Team
CC
Chris Cain
Director of Research
JS
JP Solomon
Vice President
PH
Peter Harwin
Managing Member
TK
Tomas Kiselak
Managing Member
Portfolio Breakdown
Stage Distribution
Investment Activity
DealsAvg Round Size
Portfolio
7 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Crescent Biopharma | Growth | $200M | Jun 2025 |
 Damora Therapeutics | Unknown | $284.9M | Jan 2025 |
| MMirador Therapeutics | Unknown | $250M | Jan 2025 |
 Apogee Therapeutics | Series B | $149M | Dec 2022 |
 Verona Pharma | Unknown | $200M | Jan 2020 |
 Oruka Therapeutics | Growth | $275M | — |
 Zenas BioPharma | Series C | $200M | — |
Top Co-Investors
Wellington Management4 shared
Perceptive Advisors4 shared
RTW Investments, LP3 shared
OrbiMed3 shared
Deep Track Capital3 shared
RA Capital Management3 shared
Commodore Capital3 shared
Logos Capital2 shared
Blackstone Inc.2 shared
Braidwell LP2 shared
Soleus Capital2 shared
Access Biotechnology2 shared
Vivo Capital2 shared
Fidelity Investments1 shared
BVF Partners L.P.1 shared
Frazier Life Sciences1 shared
Redmile Group1 shared
Avidity Partners1 shared
Last updated: 8 September 2026